AI based reclassification of PI-RADS 3 examinations in a biopsy-enriched cohort

Abstract This retrospective single-center study evaluated the association between automated AI categories and biopsy-detected clinically significant prostate cancer (csPCa) in 129 patients with an original PI-RADS 3 assessment. Patients were selected from an institutional biopsy series after excluding active surveillance, with MRI available for retrospective AI analysis. The reference standard was biopsy ISUP grade, and csPCa was defined as grade group ≥ 2; postoperative grading was not incorporated. Biopsy identified csPCa in 66/129 patients (51.2%). AI assigned categories 1–2 to 75 patients (58.1%), category 3 to 9 (7.0%), and categories 4–5 to 45 (34.9%). At AI category ≥ 4, sensitivity was 48.5% (95% CI 36.8–60.3%), specificity 79.4% (67.8–87.5%), positive predictive value 71.1% (56.6–82.3%), and negative predictive value 59.5% (48.8–69.4%). The ordinal AUC was 0.667 (95% CI 0.581–0.753). Among patients assigned categories 1–2, 28/75 (37.3%) had csPCa. In 111 patients with PSA density available, the AUC difference between AI and PSA density was 0.140 (95% CI − 0.021 to 0.302; p = 0.088). Automated categories showed limited discrimination in this biopsy-enriched cohort. These results do not establish safe biopsy avoidance or incremental clinical benefit.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-17
DOI
https://doi.org/10.1038/s41598-026-79488-w
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

AI based reclassification of PI-RADS 3 examinations in a biopsy-enriched cohort

Ignacio Rojas, Alfredo Aliaga, Marcelo A. Orvieto, Hugo Otaola et al.
7 links
Scientific Reports
Prostate Cancer Diagnosis and Treatment
article

AI based reclassification of PI-RADS 3 examinations in a biopsy-enriched cohort

Ignacio Rojas, Alfredo Aliaga, Marcelo A. Orvieto, Hugo Otaola, Rodrigo Pinochet, Renato Souper, Katerin Retamales, Pablo Bernier, Andres Labra, Ignacio Eltit
article en

Abstract

Abstract This retrospective single-center study evaluated the association between automated AI categories and biopsy-detected clinically significant prostate cancer (csPCa) in 129 patients with an original PI-RADS 3 assessment. Patients were selected from an institutional biopsy series after excluding active surveillance, with MRI available for retrospective AI analysis. The reference standard was biopsy ISUP grade, and csPCa was defined as grade group ≥ 2; postoperative grading was not incorporated. Biopsy identified csPCa in 66/129 patients (51.2%). AI assigned categories 1–2 to 75 patients (58.1%), category 3 to 9 (7.0%), and categories 4–5 to 45 (34.9%). At AI category ≥ 4, sensitivity was 48.5% (95% CI 36.8–60.3%), specificity 79.4% (67.8–87.5%), positive predictive value 71.1% (56.6–82.3%), and negative predictive value 59.5% (48.8–69.4%). The ordinal AUC was 0.667 (95% CI 0.581–0.753). Among patients assigned categories 1–2, 28/75 (37.3%) had csPCa. In 111 patients with PSA density available, the AUC difference between AI and PSA density was 0.140 (95% CI − 0.021 to 0.302; p = 0.088). Automated categories showed limited discrimination in this biopsy-enriched cohort. These results do not establish safe biopsy avoidance or incremental clinical benefit.

Scientific Reports
Universidad del Desarrollo (CL), Clínica Alemana (CL)
Good health and well-being
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon